Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Free Cash Flow (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Free Cash Flow data on record, last reported at -$29.7 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 58.11% year-over-year to -$29.7 million; the TTM value through Sep 2025 reached -$76.3 million, down 10.31%, while the annual FY2024 figure was -$61.0 million, 44.45% up from the prior year.
  • Free Cash Flow reached -$29.7 million in Q3 2025 per TNXP's latest filing, down from -$15.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$9.9 million in Q2 2024 and bottomed at -$36.7 million in Q1 2023.
  • Average Free Cash Flow over 3 years is -$21.1 million, with a median of -$18.8 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: surged 52.17% in 2024, then plummeted 58.11% in 2025.
  • A 3-year view of Free Cash Flow shows it stood at -$22.8 million in 2023, then soared by 35.76% to -$14.6 million in 2024, then plummeted by 103.27% to -$29.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$29.7 million in Q3 2025, -$15.4 million in Q2 2025, and -$16.6 million in Q1 2025.